Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
NCT05005793
Recruiting
Lower serum bicarbonate levels, even within the normal laboratory range, in kidney transplant recipients (KTRs) are associated with an increased risk of graft loss, cardiovascular events and mortality. Because acid retention is common in KTRs, it is plausible that alkali therapy in KTRs may also result in improved vascular and graft function. The investigators will perform a randomized, double-blinded, placebo-controlled, 12 month study in 120 KTRs to examine the effect of sodium bicarbonate the... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Metabolic Acidosis, Kidney Transplant; Complications, Vascular Diseases
Register for Updates
TReatment for ImmUne Mediated PathopHysiology
NCT04862221
Recruiting
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/28/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Register for Updates
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
NCT04545502
Recruiting
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Register for Updates
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Gender:
ALL
Ages:
Between 13 years and 90 years
Trial Updated:
05/27/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
05/27/2025
Locations: Cenexel, Englewood, Colorado
Conditions: Huntington's Disease
Register for Updates
Smart Underwear to Measure Diet-Induced Hydrogen Sulfide Production
NCT06802276
Recruiting
The purpose of this study is to evaluate the ability of a wearable Smart Underwear prototype device to quantify diet-induced changes in gut microbial hydrogen sulfide (H₂S) production. The core design is a single-site, 2-period, crossover feeding study with 6-day diet periods and an approximately 11-day washout period. Participants are fed each of two isocaloric diets designed to contrast gut microbial H₂S production (i.e., a high cysteine vs. low cysteine diet), in a random order.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Hydrogen Sulfide, Gastrointestinal Microbiome
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Aurora, Colorado
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Colorado Anschutz Medical Center, Aurora, Colorado
Conditions: Breast Cancer, Solid Tumors, Adult
Register for Updates
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT05515978
Recruiting
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multiple retrospective investigations have also shown a clinical benefit in men with prostate cancer who are incidentally treated with metformin. This pragmatic study will test the feasibility of enrollin... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Colorado Research Center, Aurora, Colorado
Conditions: Prostate Cancer
Register for Updates
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05233397
Recruiting
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/23/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT06427395
Recruiting
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Zydus US022, Aurora, Colorado
Conditions: Primary Biliary Cholangitis
Register for Updates